Navigation Links
Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology
Date:6/4/2009

BRAINTREE, Mass., June 4 /PRNewswire-FirstCall/ -- Haemonetics Corporation (NYSE: HAE) announced today that the U.S. District Court for the District of Massachusetts has made a ruling in the Company's lawsuit against Fenwal, Inc.

In January 2009, a jury issued a verdict in favor of Haemonetics, finding that Fenwal's ALYX Component Collection System consumable infringes a U.S. Haemonetics patent. The jury awarded Haemonetics $15.7 million in damages for past infringement. On June 2, 2009, the Court further ruled that, in addition to paying the damages awarded by the jury, Fenwal must stop selling the ALYX consumable by December 1, 2010 and must pay Haemonetics a 10% royalty on ALYX consumable net sales from January 30, 2009 until December 1, 2010 when the injunction takes effect. In addition, the court awarded pre-judgment interest at 5% on the unpaid damages awarded. These rulings may be appealed by Fenwal and/or Baxter.

Brian Concannon, Haemonetics' President and CEO, said, "This lawsuit was necessary to protect our Company's intellectual property. Haemonetics remains dedicated to serving the blood collection industry and working with customers to deliver blood management solutions to improve patient care and reduce healthcare costs. We are prepared to support customers through this transition period."

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, IT products, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.

    Contact:
    Julie Fallon
    Tel. (781) 356-9517
    Alt. Tel. (617) 320-2401


'/>"/>
SOURCE Haemonetics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Haemonetics Announces Launch of Faster Plasma Collection Protocol
2. Haemonetics and Octapharma AG Announce Plasma Collection Technology Contract
3. Haemonetics(R) Appoints Peter Allen as Chief Marketing Officer
4. Haemonetics Becomes Preferred Provider of Plasma Collection Products to Octapharma Europe
5. Haemonetics Announces New Subsidiary, Haemonetics Software Solutions
6. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
7. Celsense, Inc Receives NIH Grant to Translate Cell Imaging Technology for Clinical Use
8. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
9. 500th Patient Receives Berlin Heart EXCOR Pediatric Ventricular Assist Device
10. SyntheMed Receives Australian Regulatory Approval for REPEL-CV(R)
11. Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... BOSTON , Jan. 20, 2017 ... acquisition of Gen9, a pioneer in the synthesis ... Gen9,s unique expertise in assembling pathway-length synthetic DNA ... speed and capacity in the construction of new ... of industries. "Gen9 was founded to ...
(Date:1/19/2017)... and HOUSTON , ... ("NX Prenatal") today announced the formation of its ... leading clinicians and industry veterans who enhance the ... as it accelerates development of its novel prenatal ... provide medical, clinical and strategic guidance for the ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, ... Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious ... agreement for the merger of PharmAthene and Altimmune ... Novartis Venture Fund, HealthCap, Truffle Capital and Redmont ... and diversified immunotherapeutics company with four clinical stage ...
(Date:1/19/2017)... ... January 19, 2017 , ... FireflySci Inc. is a go-getter type of company ... is accounted to two main factors. The first is the amazing customer service ... supplying FireflySci products all around the world. , 2016 was a tremendous sales year ...
Breaking Biology Technology:
(Date:12/15/2016)... Dec. 14, 2016 "Increase in mobile transactions ... The mobile biometrics market is expected to grow from ... by 2022, at a CAGR of 29.3% between 2016 ... as the growing demand for smart devices, government initiatives, ... "Software component is expected to grow at a ...
(Date:12/8/2016)... , Dec. 8, 2016 Market Research Future published ... Market. The global Mobile Biometric Security and Service Market is expected ... to 2022. Market Highlights: ... , , Mobile Biometric ... due to the increasing need of authentication and security from unwanted ...
(Date:12/7/2016)... to a new market research report "Emotion Detection and Recognition Market by Technology ... End User, And Region - Global Forecast to 2021", published by MarketsandMarkets, the ... USD 36.07 Billion by 2021, at a Compound Annual Growth Rate (CAGR) of ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):